Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers

American Journal of Epidemiology

Volumn 172, Issue 1, 2010, Pages 70-80

  Zheng, Wei ^a   Danforth, Kim N ^a   Tworoger, Shelley S ^a   Goodman, Marc T ^a   Arslan, Alan A ^a   Patel, Alpa V ^a   McCullough, Marjorie L ^a   Weinstein, Stephanie J ^a   Kolonel, Laurence N ^a   Purdue, Mark P ^a   Shu, Xiao Ou ^a   Snyder, Kirk ^a   Steplowski, Emily ^a   Visvanathan, Kala ^a   Yu, Kai ^a   Zeleniuch Jacquotte, Anne ^a   Gao, Yu Tang ^a   Hankinson, Susan E ^a   Harvey, Chinonye ^a   Hayes, Richard B ^a   Henderson, Brian E ^a   Horst, Ronald L ^a   Helzlsouer, Kathy J ^a   more..

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Case control studies; Cohort studies; Ovarian neoplasms; Prospective studies; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D;

CANCER; COHORT ANALYSIS; COMPARATIVE STUDY; GENETIC ANALYSIS; HEALTH RISK; POLYMORPHISM; PUBLIC HEALTH; VITAMIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; VITAMIN BLOOD LEVEL; BLOOD; CHINA; COHORT ANALYSIS; FINLAND; OBESITY; OVARY TUMOR; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; UNITED STATES; VITAMIN D DEFICIENCY;

ADULT; CASE-CONTROL STUDIES; CHINA; COHORT STUDIES; FEMALE; FINLAND; HUMANS; LOGISTIC MODELS; OVARIAN NEOPLASMS; OVERWEIGHT; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 78549276708     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq118     Document Type: Article

References (46)

1. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of and rogens and progesterone. J Natl Cancer Inst. 1998;90(23):1774-1786.
2. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-2529.
3. Ahonen MH, Zhuang YH, Aine R, et al. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 2000; 86(1):40-46.
4. Anderson MG, Nakane M, Ruan X, et al. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol. 2006;57(2):234-240.
5. Friedrich M, Rafi L, Mitschele T, et al. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 2003;164: 239-246.
6. Panda DK, Miao D, Tremblay ML, et al. Targeted ablation of the 25-hydroxyvitamin D 1α-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A. 2001;98(13):7498-7503.
7. 3 in gynecologic neoplasms. Gynecol Oncol. 1992;44(2):131-136.
8. 3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. Anticancer Res. 2002;22(4): 2261-2267.
9. Yoshizawa T, Handa Y, Uematsu Y, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet. 1997;16(4):391-396.
10. 3. Endocrinology. 1983; 112(1):200-206.
11. 3through the downregulation of telomerase. J Biol Chem. 2004;279(51):53213-53221.
12. 3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem. 2003;278(48):48030-48040.
13. Kemmis CM, Salvador SM, Smith KM, et al. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr. 2006;136(4):887-892.
14. 3in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem. 2004;279(24):25260-25267.
15. 3 growth response of OVCAR-3 ovarian cancer cells. Int J Cancer. 2004;108(3):367-373.
16. 3 combined with retinoic acid or dexamethasone. Anticancer Drugs. 1995;6(4):562-569.
17. Zhang X, Jiang F, Li P, et al. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res. 2005;11(1):323-328.
18. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control. 2005;16(2):83-95.
19. Freedman DM, Dosemeci M, McGlynn K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup Environ Med. 2002;59(4):257-262.
20. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006; 96(2):252-261.
21. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002;94(6):1867-1875.
22. Grant WB, Garland CF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res. 2006;26(4A):2687-2699.
23. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol. 1994; 23(6):1133-1136.
24. Bidoli E, La Vecchia C, Talamini R, et al. Micronutrients and ovarian cancer: a case-control study in Italy. Ann Oncol. 2001; 12(11):1589-1593.
25. Genkinger JM, Hunter DJ, Spiegelman D, et al. Dairy products and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2006;15(2):364-372.
26. Goodman MT, Wu AH, Tung KH, et al. Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol. 2002;156(2):148-157.
27. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, et al. Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. Oncology. 2002; 63(2):151-157.
28. Koralek DO, Bertone-Johnson ER, Leitzmann MF, et al. Relationship between calcium, lactose, vitamin D, and dairy products and ovarian cancer. Nutr Cancer. 2006;56(1):22-30.
29. Tworoger SS, Lee IM, Buring JE, et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of incident ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(4):783-788.
30. Toriola AT, Surcel HM, Agborsangaya C, et al. Serum 25-hydroxyvitamin D and the risk of ovarian cancer. Eur J Cancer. 2010;46(2):364-369.
31. Arslan AA, Clendenen TV, Koenig KL, et al. Circulating vitamin D and risk of epithelial ovarian cancer. J Oncol. 2009; 2009:672492. (doi:10.1155/2009/ 672492).
32. Tworoger SS, Gates MA, Lee IM, et al. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res. 2009;69(5):1885-1891.
33. Lurie G, Wilkens LR, Thompson PJ, et al. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2566-2571.
34. Clendenen TV, Arslan AA, Koenig KL, et al. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett. 2008;260(1-2):209-215.
35. Gallicchio L, Helzlsouer K, Chow WH, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers design and methods. Am J Epidemiol. 2010;172(1):10-20.
36. Chen VW, Ruiz B, Killeen JL, et al. Pathology and classification of ovarian tumors. Cancer. 2003;97(10 suppl):2631-2642.
37. Wagner D, Hanwell HE, Vieth R. An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem. 2009;42(15):1549-1556.
38. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr. 2008;88(6): 1519-1527.
39. Viechtbauer W. MiMa: an S-Plus/R function to fit meta-analytic mixed-, random-, and fixed-effects models. Maastricht, the Netherlands: Maastricht University; 2006. (http://www.wvbauer.com/downloads.html). (Accessed February 6, 2009).
40. Schouten LJ, Rivera C, Hunter DJ, et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2008;17(4):902-912.
41. Arunabh S, Pollack S, Yeh J, et al. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab. 2003;88(1):157-161.
42. Gómez JM, Maravall FJ, Gómez N, et al. Relationship between 25-(OH) D3, the IGF-I system, leptin, anthropometric and body composition variables in a healthy, randomly selected population. Horm Metab Res. 2004;36(1):48-53.
43. Lucas JA, Bolland MJ, Grey AB, et al. Determinants of vitamin D status in older women living in a subtropical climate. Osteoporos Int. 2005;16(12):1641-1648.
44. Snijder MB, van Dam RM, Visser M, et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab. 2005;90(7):4119-4123.
45. Brouwer DA, van Beek J, Ferwerda H, et al. Rat adipose tissue rapidly accumulates and slowly releases an orally-administered high vitamin D dose. Br J Nutr. 1998;79(6):527-532.
46. Platz EA, Leitzmann MF, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004;15(3):255-265.